Medicsight PLC, a subsidiary of MGT Capital Investments, Inc. (MGT), announced that the National U.S. Computerized Tomography (CT) Colonography Trial (ACRIN study 6664), shows CT colonography was able to detect 90% of asymptomatic patients with colonic polyps or cancers of 10mm and larger, compared with the gold standard examination of optical colonoscopy. The results are expected to lead to wider adoption of CT colonography (also known as CTC) as a routine screening examination for colorectal cancer.
KNOBIAS DISCLAIMER: All statements made in this article were made by the Company and do not in any way reflect the opinions of Knobias. Knobias is not a registered broker-dealer, nor investment advisor, and does not endorse or recommend any securities mentioned. This story is provided for informational purposes only and is not intended for trading purposes. Knobias shall not be liable for any actions taken in reliance of any information provided herein. Republication or redistribution of Knobias content is expressly prohibited without prior written consent of Knobias.com, LLC.
ABOUT KNOBIAS: Knobias is a premier financial information provider of trading and investing data covering all U.S. equities for investors and security professionals. Knobias is best described by its three major components: Real-time desktop applications providing quotes, charts, level 2, analysis etc.; Knobias RAiDAR providing thousands of real-time news stories, alerts and documents daily; Knobias fundamentals providing a comprehensive database of fundamental research information.
If your company wishes to participate in the EventX newswire, please contact Knobias: http://www.knobias.com
Knobias.com, LLC 601-978-3399 601-978-3675 info@knobias.com www.knobias.com/cmtx

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index